To me this looks good, but I wonder what the market will make of this: “An uneven profit profile for CSL is expected for the first and second half results, due to the seasonality of the influenza business and the timing of expenses – particularly research and development,” Mr. Perreault added.
Ann: Half Year Results Analyst Presentation, page-3
-
- There are more pages in this discussion • 188 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$301.10 |
Change
-4.570(1.50%) |
Mkt cap ! $145.5B | |||
| Open | High | Low | Value | Volume |
| $301.50 | $305.00 | $299.50 | $211.2M | 701.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1200 | $301.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $301.11 | 734 | 1 |
View Market Depth
| Last trade - 16.10pm 05/08/2024 (20 minute delay) ? |
| CSL (ASX) Chart |